Aurobindo Pharma Ltd. has disclosed that the U.S. Food and Drug Administration (USFDA) issued a Form 483 with 11 procedural observations following a recent inspection of its North Carolina-based manufacturing unit, operated by its wholly owned subsidiary, Aurolife Pharma LLC. Conducted between March 24 and April 10, 2025, the inspection concluded with compliance concerns that, while non-critical, have prompted the company to implement corrective actions.